anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Amoxicillin
Trial phase: Not Applicable
ATC code: A02BD01 | A02BD03 | A02BD04 | A02BD05 | A02BD06 | A02BD07 | A02BD10 | A02BD11 | A02BD12 | A02BD13 | A02BD14 | A02BD15 | A02BD16 | J01CA04 | J01CR50
SMILES: [H][C@]12SC(C)(C)[C@H](C(=O)O)N1C(=O)[C@H]2NC(=O)[C@H](N)c1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 166
Group description: a dual therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid for 7 days, followed by a quadruple therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for a further 7 days

Hybrid therapy: a dual therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid for 7 days, followed by a quadruple therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for a further 7 days
Eligibility criteria:
Inclusion Criteria:

Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis

Exclusion Criteria:

previous H pylori-eradication therapy
ingestion of antibiotics or bismuth within the prior 4 weeks
patients with allergic history to the medications used
patients with previous gastric surgery
the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
pregnant women
Intervention: Acetate
Trial phase: Not Applicable
SMILES: CC(=O)[O-]
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: IV acetate given during magnetic resonance scan

acetate: acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
Eligibility criteria:
Inclusion Criteria-all:

Subjects who are age 21-55,
Subjects who are proficient in English ,
Subjects who understand the nature of the study,
Subjects who have signed an informed consent,
Subjects who are non-smoking (defined as fewer than 20 cigarettes lifetime),

Inclusion Criteria-moderate drinkers:

Subjects who are moderate drinkers (male:1-14 drinks per week; female: 1-7 drinks per week).
Subjects who have drunk at least 2 drinks in one hour in the past, and have no history of dependence on drugs or alcohol

Inclusions-AUD:

(1) Subjects who meet DSM-V criteria for lifetime history of Alcohol Use Disorder (AUD)

Exclusion Criteria-all:

Subjects who have a "facial flushing" response to alcohol,
Subjects who are pregnant or nursing,
Subjects who have major medical problems including diabetes, high blood pressure (> 150/90), prior neurological or psychiatric history (schizophrenia, bipolar, or current major depressive disorder), epilepsy (alcohol withdrawal seizures is not an exclusion),
Subjects who have been told they have or been diagnosed with liver or kidney disease,
Subjects who have chronic gastrointestinal disease,
Subjects who are obese (BMI>30 kg/m2),
Subjects who take psychoactive medications,
Subjects who have prior head trauma resulting in loss of consciousness >15 minutes,
Subjects who have Magnetic Resonance (MR) exclusions which include claustrophobia, intracranial, orbital, or spinal metal implants, pacemakers, cochlear implants, cardiac stents or other non-MR-compatible implants or devices.
Intervention: Ethanol
Trial phase: Not Applicable
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: jello given before magnetic resonance scan

alcohol: jello containing alcohol, jello containing no alcohol, fMRI scan.
Eligibility criteria:
Inclusion Criteria-all:

Subjects who are age 21-55,
Subjects who are proficient in English ,
Subjects who understand the nature of the study,
Subjects who have signed an informed consent,
Subjects who are non-smoking (defined as fewer than 20 cigarettes lifetime),

Inclusion Criteria-moderate drinkers:

Subjects who are moderate drinkers (male:1-14 drinks per week; female: 1-7 drinks per week).
Subjects who have drunk at least 2 drinks in one hour in the past, and have no history of dependence on drugs or alcohol

Inclusions-AUD:

(1) Subjects who meet DSM-V criteria for lifetime history of Alcohol Use Disorder (AUD)

Exclusion Criteria-all:

Subjects who have a "facial flushing" response to alcohol,
Subjects who are pregnant or nursing,
Subjects who have major medical problems including diabetes, high blood pressure (> 150/90), prior neurological or psychiatric history (schizophrenia, bipolar, or current major depressive disorder), epilepsy (alcohol withdrawal seizures is not an exclusion),
Subjects who have been told they have or been diagnosed with liver or kidney disease,
Subjects who have chronic gastrointestinal disease,
Subjects who are obese (BMI>30 kg/m2),
Subjects who take psychoactive medications,
Subjects who have prior head trauma resulting in loss of consciousness >15 minutes,
Subjects who have Magnetic Resonance (MR) exclusions which include claustrophobia, intracranial, orbital, or spinal metal implants, pacemakers, cochlear implants, cardiac stents or other non-MR-compatible implants or devices.
Intervention: NORETHINDRONE ACETATE
Trial phase: Phase 2
SMILES: C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Sex: Female
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Norethindrone acetate 5 mg po daily x 6 months

Norethindrone acetate
Eligibility criteria:
Inclusion Criteria:

Surgically confirmed endometriosis
Age between 15-40 y, and premenopausal
Pelvic pain score ≥3 on a Visual Analog Scaleover the last month

Exclusion Criteria:

Use of other concurrent hormone medications (such as birth control pills)
Impaired liver function (ALT > 2x normal) or liver disease (cirrhosis, hepatitis)
Pregnancy
Breast cancer
Active thromboembolic disease
Uncontrolled hypertension, history of cardiac valve disorder, history of fibrotic disorders
Intervention: Lubiprostone
Trial phase: Phase 2
ATC code: A06AX03
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(=O)O)[C@@]1([H])CC[C@](O)(C(F)(F)CCCC)O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Participants receive 8 mcg lubiprostone capsules BID
Eligibility criteria:
Inclusion Criteria:

Subject meets the diagnosis of IBS-M or IBS-U as confirmed using the adapted ROME III Diagnostic Questionnaire for Adult Functional GI Disorders.
Subject Screening diary entries must show an average worst abdominal pain in the past 24 hours score of at least 4 on a 11-point scale.
Subject must be on a stable dose of selective serotonin re-uptake inhibitors (SSRIs), serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors if taking antidepressants.

Exclusion Criteria:

Subject has current diagnosis of IBS with diarrhea (IBS-D) or IBS with constipation (IBS-C), according to Rome III Criteria.
Any gastrointestinal (GI) condition, other than IBS-related, affecting GI motility or defecation.
Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication.
Intervention: Azithromycin
Trial phase: Not Applicable
ATC code: J01FA10 | J01RA07 | J01RA16 | S01AA26
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 28
Group description: The azithromycin group will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Eligibility criteria:
Inclusion Criteria:

children with a diagnosis of chronic lung disease (CLD) secondary to bronchopulmonary dysplasia (BPD) as defined by ATS.
children who receive primary care at High Risk Infant Clinic or High Risk Children's Clinic

Exclusion Criteria:

Children with Cystic Fibrosis or bronchiectasis
Children with cardiac arrhythmias
Children with cyanotic heart disease
Children with colitis
Children with a known Macrolide allergy
Children taking medications known to interact with macrolides
Children with short bowel syndrome
Children with kidney or liver failure
Intervention: Indium In-111 Pentetreotide
Trial phase: Not Applicable
ATC code: V09IB01
SMILES: CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1.[H+].[In+3]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
Eligibility criteria:
Inclusion Criteria:

Individuals aged 18 or older
Documentation of biopsy-proven sarcoidosis OR patients with typical findings on FDG PET and MRI without previous biopsy
Clinical suspicion of cardiac involvement defined as the presence of any of the following: high-degree A-V nodal block, complete bundle branch block, reduced left or right ventricular systolic function, any cardiac arrhythmia, and/or unexplained chest pain, dyspnea or syncope
PET/CT imaging demonstrating abnormal myocardial FDG uptake consistent with active inflammatory myocardium.

Exclusion Criteria:

Initiation of steroids or any other immunosuppressive medication(s) following the completion of FDG-PET, as these medications, in theory, may subsequently suppress OctreoScan or DOTATATE uptake in the heart.
Patients with history of neuroendocrine tumors (specially insulinomas)
Patients taking the medication Octreotide
Patients on total parenteral nutrition (TPN)
Women who are pregnant or breastfeeding
Intervention: Omeprazole
Trial phase: Not Applicable
ATC code: A02BC01 | A02BC05 | A02BD01 | A02BD05 | A02BD06 | A02BD16 | M01AE52
SMILES: COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.

esomeprazole+amox+levo+tetra: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
Eligibility criteria:
Inclusion Criteria:

positive results of both rapid urease test and histology,
a positive result of urea breath test,
or a positive result of culture.

Exclusion Criteria:

ingestion of antibiotics, bismuth, or proton pump inhibitor（PPI）within the prior 4 weeks,
patients with allergic history to the medications used,
patients with previous gastric surgery,
the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia),
pregnant women
Intervention: Omeprazole
Trial phase: Not Applicable
ATC code: A02BC01 | A02BC05 | A02BD01 | A02BD05 | A02BD06 | A02BD16 | M01AE52
SMILES: COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.

esomeprazole+amox+levo: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
Eligibility criteria:
Inclusion Criteria:

positive results of both rapid urease test and histology,
a positive result of urea breath test,
or a positive result of culture.

Exclusion Criteria:

ingestion of antibiotics, bismuth, or proton pump inhibitor（PPI）within the prior 4 weeks,
patients with allergic history to the medications used,
patients with previous gastric surgery,
the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia),
pregnant women
Intervention: Betamethasone
Trial phase: Phase 3
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 126
Group description: A single intraocular dose of dexamethasone (517 mcg) at the conclusion of cataract surgery
Eligibility criteria:
Inclusion Criteria:

undergoing cataract surgery

Exclusion Criteria:

glaucoma patient, pregnancy, allergy to dexamethasone
Intervention: Berberine
Trial phase: Phase 3
SMILES: COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 1500 mg berberine each 24 hours
Eligibility criteria:
Inclusion Criteria:

A. Men and women

B. Accomplished age 30 to 60 years

C. Diagnosis of mixed dyslipidemia established to meet the following criteria:

Total cholesterol > 5,17 mmol/l.
Triglycerides > 1,7 mmol/l.

D. BMI of 25 kg / m^2 to 39.9 kg / m^2, weight stable over the past three months, defined as a variability in the lower body weight of 5%.

E. No drug treatment for lipid profile 3 months prior to baseline.

F. Women must ensure a non-hormonal method to avoid pregnancy during the study period.

G. Written information consent

Exclusion Criteria:

A. Removal for informed consent letter

B. Loss of monitoring

C. Presence of serious adverse event

D. Adherence to treatment <80%

E. Consumption of drugs known about lipid profile, glucose metabolism, blood pressure and body weight during the intervention period influence

F. Intolerance or not tolerability or hypersensitivity to the compounds used in the study
Intervention: Bezafibrate
Trial phase: Phase 3
ATC code: C10AB02
SMILES: CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 400 mg bezafibrate each 24 hours
Eligibility criteria:
Inclusion Criteria:

A. Men and women

B. Accomplished age 30 to 60 years

C. Diagnosis of mixed dyslipidemia established to meet the following criteria:

Total cholesterol > 5,17 mmol/l.
Triglycerides > 1,7 mmol/l.

D. BMI of 25 kg / m^2 to 39.9 kg / m^2, weight stable over the past three months, defined as a variability in the lower body weight of 5%.

E. No drug treatment for lipid profile 3 months prior to baseline.

F. Women must ensure a non-hormonal method to avoid pregnancy during the study period.

G. Written information consent

Exclusion Criteria:

A. Removal for informed consent letter

B. Loss of monitoring

C. Presence of serious adverse event

D. Adherence to treatment <80%

E. Consumption of drugs known about lipid profile, glucose metabolism, blood pressure and body weight during the intervention period influence

F. Intolerance or not tolerability or hypersensitivity to the compounds used in the study
Intervention: MK-1064
Trial phase: Phase 1
SMILES: COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
Eligibility criteria:
Inclusion Criteria:

Body Mass Index (BMI) ≤31 kg/m^2
In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests
Nonsmoker and has not used nicotine or nicotine-containing products for at least approximately 6 months

Exclusion Criteria:

Mentally or legally incapacitated, significant emotional problems at screening or expected during the conduct of the study or history of a clinically significant psychiatric disorder within the last 10 years
History of any persistent sleep abnormality (including difficulty falling asleep, difficulty staying asleep) lasting for 3 months or more, or history of obstructive sleep apnea, restless legs syndrome, or narcolepsy of any duration
Participant has experienced poor quality sleep (including difficulty falling asleep, difficulty staying asleep) for at least 4 of 7 nights per week in the past 30 days prior to screening
Participant works a night shift and is not able to avoid night shift work a minimum of 1 week before each treatment period
Participant has traveled across 3 or more time zones (transmeridian travel) in the last 2 weeks prior to study
Unwilling or unable to consume a standard high fat breakfast
History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
History of seizures, epilepsy, stroke, peripheral neuropathy, or other clinically significant neurological disease or cognitive impairment
History of cancer
History of cataplexy
Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies, beginning approximately 2 weeks prior to administration of the initial dose of study drug and throughout the study
Participant consumes >3 servings of alcohol a day
Participant consumes >6 caffeine servings a day
Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks prior to screening
History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
Is currently a regular user of any illicit drugs or has a history of drug (including alcohol) abuse within 2 years of screening
Is a regular user of sedative-hypnotic agents
Intervention: MK-1064
Trial phase: Phase 1
SMILES: COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
Eligibility criteria:
Inclusion Criteria:

Body Mass Index (BMI) ≤31 kg/m^2
In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests
Nonsmoker and has not used nicotine or nicotine-containing products for at least approximately 6 months

Exclusion Criteria:

Mentally or legally incapacitated, significant emotional problems at screening or expected during the conduct of the study or history of a clinically significant psychiatric disorder within the last 10 years
History of any persistent sleep abnormality (including difficulty falling asleep, difficulty staying asleep) lasting for 3 months or more, or history of obstructive sleep apnea, restless legs syndrome, or narcolepsy of any duration
Participant has experienced poor quality sleep (including difficulty falling asleep, difficulty staying asleep) for at least 4 of 7 nights per week in the past 30 days prior to screening
Participant works a night shift and is not able to avoid night shift work a minimum of 1 week before each treatment period
Participant has traveled across 3 or more time zones (transmeridian travel) in the last 2 weeks prior to study
Unwilling or unable to consume a standard high fat breakfast
History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
History of seizures, epilepsy, stroke, peripheral neuropathy, or other clinically significant neurological disease or cognitive impairment
History of cancer
History of cataplexy
Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies, beginning approximately 2 weeks prior to administration of the initial dose of study drug and throughout the study
Participant consumes >3 servings of alcohol a day
Participant consumes >6 caffeine servings a day
Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks prior to screening
History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
Is currently a regular user of any illicit drugs or has a history of drug (including alcohol) abuse within 2 years of screening
Is a regular user of sedative-hypnotic agents
Intervention: MK-1064
Trial phase: Phase 1
SMILES: COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
Eligibility criteria:
Inclusion Criteria:

Body Mass Index (BMI) ≤31 kg/m^2
In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests
Nonsmoker and has not used nicotine or nicotine-containing products for at least approximately 6 months

Exclusion Criteria:

Mentally or legally incapacitated, significant emotional problems at screening or expected during the conduct of the study or history of a clinically significant psychiatric disorder within the last 10 years
History of any persistent sleep abnormality (including difficulty falling asleep, difficulty staying asleep) lasting for 3 months or more, or history of obstructive sleep apnea, restless legs syndrome, or narcolepsy of any duration
Participant has experienced poor quality sleep (including difficulty falling asleep, difficulty staying asleep) for at least 4 of 7 nights per week in the past 30 days prior to screening
Participant works a night shift and is not able to avoid night shift work a minimum of 1 week before each treatment period
Participant has traveled across 3 or more time zones (transmeridian travel) in the last 2 weeks prior to study
Unwilling or unable to consume a standard high fat breakfast
History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
History of seizures, epilepsy, stroke, peripheral neuropathy, or other clinically significant neurological disease or cognitive impairment
History of cancer
History of cataplexy
Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies, beginning approximately 2 weeks prior to administration of the initial dose of study drug and throughout the study
Participant consumes >3 servings of alcohol a day
Participant consumes >6 caffeine servings a day
Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks prior to screening
History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
Is currently a regular user of any illicit drugs or has a history of drug (including alcohol) abuse within 2 years of screening
Is a regular user of sedative-hypnotic agents